MACOPHARMA (UK) LIMITEDActive

Company number 01986987Private limited companyIncorporated 1986

Key figures

£1,084,863+9.1%
Net assets 2025
+20.2%
Average annual growth 2021–2025
0500 k1 m1.5 m20212022202320242025

Like most small UK companies, MACOPHARMA (UK) LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2025
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
02 m4 m6 m20212022202320242025

Dividends

from the accounts
2021

Dividends paid in the financial year: £195,185 (208% of the profit for the year).

Filed accounts2021–2025
20212022202320242025
Turnover14,009,392————
Profit for the year93,715————
Cash at bank and in hand76,961164,23720,62317,54022,329
Total assets4,157,2632,954,0662,706,8632,996,9213,640,792
Total liabilities—————
Net assets / total equity520,427715,200917,652994,3641,084,863
Average number of employees887911
Average pay (per year)56,007————
Dividends paid195,185————

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: MACOPHARMA (UK) LIMITED

Company

MACOPHARMA (UK) LIMITED is a private limited company registered with Companies House under company number 01986987. It was incorporated on 7 Feb 1986. Its status is active. The registered office is in London (EC2R). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100).

Accounts

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts. Net assets were £1,084,863, up 9.1% on the previous year. Cash at bank and in hand was £22,329. The company had an average of 11 employees. Figures are available for 5 financial years (2021–2025).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 11 May 2027.